The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Achondroplasia Treatment Market Research Report 2025
Synopsis
Achondroplasia is a disorder of bone growth that prevents the changing of cartilage (particularly in the long bones of the arms and legs) to bone. It is characterized by dwarfism, limited range of motion at the elbows, large head size (macrocephaly), small fingers, and normal intelligence. Achondroplasia (ACH) is a rare disease that causes short stature (adult height of approximately 130 cm for males and approximately 125 cm for females) with short limbs. There is no effective treatment available, and this disease is designated as an intractable disease by the Ministry of Health, Labour and Welfare. This disease results mainly from a genetic defect in FGFR3 (fibroblast growth factor type 3 receptor). This genetic change causes the receptor to be overly active to growth factors such as FGF2, which leads to reduced growth of chondrocytes, resulting a short stature. ACH occurs in a frequency of 1 in approximately 25,000 normal live births and is estimated to affect approximately 250,000 people worldwide.
The global Achondroplasia Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The main global Achondroplasia Treatment players include Ascendis Pharma, BioMarin, Ribomic, QED Therapeutics, Pfizer, Astellas, etc. North America is the largest consumer market for Achondroplasia Treatment, accounting for about 46%, followed by Europe and China. In terms of type, CNP Analogue is the largest segment, with a share over 57%. And in terms of application, the largest application is Hospital, followed by Retail Pharmacy.
This report aims to provide a comprehensive presentation of the global market for Achondroplasia Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Achondroplasia Treatment.
Report Scope
The Achondroplasia Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Achondroplasia Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Achondroplasia Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Ascendis Pharma
BioMarin
Ribomic
QED Therapeutics
Pfizer
Astellas
Segment by Type
CNP Analogue
Ligand Trap
TKI
Others
Segment by Application
Hospital
Retail Pharmacy
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Achondroplasia Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Achondroplasia is a disorder of bone growth that prevents the changing of cartilage (particularly in the long bones of the arms and legs) to bone. It is characterized by dwarfism, limited range of motion at the elbows, large head size (macrocephaly), small fingers, and normal intelligence. Achondroplasia (ACH) is a rare disease that causes short stature (adult height of approximately 130 cm for males and approximately 125 cm for females) with short limbs. There is no effective treatment available, and this disease is designated as an intractable disease by the Ministry of Health, Labour and Welfare. This disease results mainly from a genetic defect in FGFR3 (fibroblast growth factor type 3 receptor). This genetic change causes the receptor to be overly active to growth factors such as FGF2, which leads to reduced growth of chondrocytes, resulting a short stature. ACH occurs in a frequency of 1 in approximately 25,000 normal live births and is estimated to affect approximately 250,000 people worldwide.
The global Achondroplasia Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The main global Achondroplasia Treatment players include Ascendis Pharma, BioMarin, Ribomic, QED Therapeutics, Pfizer, Astellas, etc. North America is the largest consumer market for Achondroplasia Treatment, accounting for about 46%, followed by Europe and China. In terms of type, CNP Analogue is the largest segment, with a share over 57%. And in terms of application, the largest application is Hospital, followed by Retail Pharmacy.
This report aims to provide a comprehensive presentation of the global market for Achondroplasia Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Achondroplasia Treatment.
Report Scope
The Achondroplasia Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Achondroplasia Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Achondroplasia Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Ascendis Pharma
BioMarin
Ribomic
QED Therapeutics
Pfizer
Astellas
Segment by Type
CNP Analogue
Ligand Trap
TKI
Others
Segment by Application
Hospital
Retail Pharmacy
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Achondroplasia Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Achondroplasia Treatment Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 CNP Analogue
1.2.3 Ligand Trap
1.2.4 TKI
1.2.5 Others
1.3 Market by Application
1.3.1 Global Achondroplasia Treatment Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Achondroplasia Treatment Market Perspective (2019-2030)
2.2 Achondroplasia Treatment Growth Trends by Region
2.2.1 Global Achondroplasia Treatment Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Achondroplasia Treatment Historic Market Size by Region (2019-2024)
2.2.3 Achondroplasia Treatment Forecasted Market Size by Region (2025-2030)
2.3 Achondroplasia Treatment Market Dynamics
2.3.1 Achondroplasia Treatment Industry Trends
2.3.2 Achondroplasia Treatment Market Drivers
2.3.3 Achondroplasia Treatment Market Challenges
2.3.4 Achondroplasia Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Achondroplasia Treatment Players by Revenue
3.1.1 Global Top Achondroplasia Treatment Players by Revenue (2019-2024)
3.1.2 Global Achondroplasia Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Achondroplasia Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Achondroplasia Treatment Revenue
3.4 Global Achondroplasia Treatment Market Concentration Ratio
3.4.1 Global Achondroplasia Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Achondroplasia Treatment Revenue in 2023
3.5 Achondroplasia Treatment Key Players Head office and Area Served
3.6 Key Players Achondroplasia Treatment Product Solution and Service
3.7 Date of Enter into Achondroplasia Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Achondroplasia Treatment Breakdown Data by Type
4.1 Global Achondroplasia Treatment Historic Market Size by Type (2019-2024)
4.2 Global Achondroplasia Treatment Forecasted Market Size by Type (2025-2030)
5 Achondroplasia Treatment Breakdown Data by Application
5.1 Global Achondroplasia Treatment Historic Market Size by Application (2019-2024)
5.2 Global Achondroplasia Treatment Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Achondroplasia Treatment Market Size (2019-2030)
6.2 North America Achondroplasia Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Achondroplasia Treatment Market Size by Country (2019-2024)
6.4 North America Achondroplasia Treatment Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Achondroplasia Treatment Market Size (2019-2030)
7.2 Europe Achondroplasia Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Achondroplasia Treatment Market Size by Country (2019-2024)
7.4 Europe Achondroplasia Treatment Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Achondroplasia Treatment Market Size (2019-2030)
8.2 Asia-Pacific Achondroplasia Treatment Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Achondroplasia Treatment Market Size by Region (2019-2024)
8.4 Asia-Pacific Achondroplasia Treatment Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Achondroplasia Treatment Market Size (2019-2030)
9.2 Latin America Achondroplasia Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Achondroplasia Treatment Market Size by Country (2019-2024)
9.4 Latin America Achondroplasia Treatment Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Achondroplasia Treatment Market Size (2019-2030)
10.2 Middle East & Africa Achondroplasia Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Achondroplasia Treatment Market Size by Country (2019-2024)
10.4 Middle East & Africa Achondroplasia Treatment Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Ascendis Pharma
11.1.1 Ascendis Pharma Company Detail
11.1.2 Ascendis Pharma Business Overview
11.1.3 Ascendis Pharma Achondroplasia Treatment Introduction
11.1.4 Ascendis Pharma Revenue in Achondroplasia Treatment Business (2019-2024)
11.1.5 Ascendis Pharma Recent Development
11.2 BioMarin
11.2.1 BioMarin Company Detail
11.2.2 BioMarin Business Overview
11.2.3 BioMarin Achondroplasia Treatment Introduction
11.2.4 BioMarin Revenue in Achondroplasia Treatment Business (2019-2024)
11.2.5 BioMarin Recent Development
11.3 Ribomic
11.3.1 Ribomic Company Detail
11.3.2 Ribomic Business Overview
11.3.3 Ribomic Achondroplasia Treatment Introduction
11.3.4 Ribomic Revenue in Achondroplasia Treatment Business (2019-2024)
11.3.5 Ribomic Recent Development
11.4 QED Therapeutics
11.4.1 QED Therapeutics Company Detail
11.4.2 QED Therapeutics Business Overview
11.4.3 QED Therapeutics Achondroplasia Treatment Introduction
11.4.4 QED Therapeutics Revenue in Achondroplasia Treatment Business (2019-2024)
11.4.5 QED Therapeutics Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Detail
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Achondroplasia Treatment Introduction
11.5.4 Pfizer Revenue in Achondroplasia Treatment Business (2019-2024)
11.5.5 Pfizer Recent Development
11.6 Astellas
11.6.1 Astellas Company Detail
11.6.2 Astellas Business Overview
11.6.3 Astellas Achondroplasia Treatment Introduction
11.6.4 Astellas Revenue in Achondroplasia Treatment Business (2019-2024)
11.6.5 Astellas Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Chemicals Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
